A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2013

At a glance

  • Drugs Ranolazine (Primary) ; Ranolazine (Primary)
  • Indications Diastolic heart failure
  • Focus Therapeutic Use
  • Acronyms RALI-DHF
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database EudraCT2009-017168-17).
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top